Related Experiment Videos
Distribution of [2-14C]merbarone in mice by autoradiography of whole-body cryosections
Abstract:
The distribution of radiolabel in male mice was studied by autoradiography of whole-body cryosections at intervals during 24 h after i.v. injection (46.6 mg/kg) and during 4 h after oral administration (140 mg/kg) of [2-14C]merbarone. Following injection, radioactivity levels in the blood and highly vascular tissues declined to 8 h at which time only low levels were present in the systemic circulation. Only very low levels were seen in the brain and spinal cord at 0.5-3 min after dosing and levels were barely above background in autoradiograms obtained at 0.5-1 h. Radiolabel was concentrated in those regions which lack an effective blood-brain barrier particularly within the choroid plexuses. Radioactivity was rapidly taken up by the liver and kidneys and as the blood and body radioactivity levels decreased, these organs remained densely labeled. Significant biliary excretion had occurred by 30 min and the autoradiograms to 24 h showed radiolabeled compounds in the intestinal lumen. Between 1 and 8 h, the liver exhibited a stippled appearance as a result of labeling around branches of the portal vein due to enterohepatic recycling. The stippling was substantially diminished at 16 h. High levels of radioactivity were present in the kidney at 0.5-3 min after injection with both the kidney cortex and medulla initially densely labeled. At 4 h and thereafter, the radioactivity levels in the kidney were lower with most of the labeled compounds in the medulla. Accumulation in the liver and kidney was very low at 16-24 h after dosing and most of the merbarone dose had cleared from the body. Rapid absorption of merbarone occurred after oral administration with radiolabel first observed in the liver and kidney at 3-6 min after dosing. Peak levels in these organs and systemically were seen between 0.5 and 2 h. At 4 h, the radioactivity had largely cleared from the systemic circulation. The liver exhibited a stippled appearance soon after oral dosing similar to that observed following i.v. dosing affording evidence for enterohepatic recycling after i.v. administration. The relatively low systemic levels observed after oral dosing suggests that the liver binds much of the absorbed drug and its metabolites limiting the levels which reach the systemic circulation.
Insights
This study tracked [2-14C]merbarone distribution in mice after intravenous and oral doses. Radiolabel rapidly distributed to the liver and kidneys, with evidence of enterohepatic recycling, and was largely cleared within 24 hours.
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Toxicology and Pharmacology
- Radiopharmaceutical Distribution Studies
Background:
- Understanding drug distribution is crucial for assessing efficacy and safety.
- Merbarone's pharmacokinetic profile requires detailed investigation.
Purpose of the Study:
- To elucidate the distribution and excretion pathways of [2-14C]merbarone in male mice.
- To investigate the impact of administration route (intravenous vs. oral) on merbarone distribution.
Main Methods:
- Whole-body autoradiography of cryosections in male mice following intravenous and oral administration of [2-14C]merbarone.
- Quantitative analysis of radiolabel distribution over 24 hours post-intravenous injection and 4 hours post-oral administration.
Main Results:
- Intravenous [2-14C]merbarone rapidly distributed to highly vascular tissues, liver, and kidneys, with significant biliary excretion and evidence of enterohepatic recycling.
- Oral administration showed rapid absorption, with peak liver and kidney levels observed early, suggesting substantial hepatic uptake limiting systemic circulation.
- Low levels of radiolabel were detected in the brain and spinal cord, with higher concentrations in regions lacking a robust blood-brain barrier.
Conclusions:
- Merbarone undergoes rapid distribution and elimination, primarily via biliary excretion, with significant enterohepatic recycling influencing its pharmacokinetic profile.
- Hepatic uptake plays a critical role in modulating systemic merbarone levels after oral administration.
- The drug demonstrates limited penetration across the blood-brain barrier, concentrating instead in organs like the liver and kidneys.